febuxostat has been researched along with ipragliflozin in 1 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (ipragliflozin) | Trials (ipragliflozin) | Recent Studies (post-2010) (ipragliflozin) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 175 | 45 | 172 |
| Protein | Taxonomy | febuxostat (IC50) | ipragliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 1.876 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0076 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
1 review(s) available for febuxostat and ipragliflozin
| Article | Year |
|---|---|
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |